The performance of companies tied to iconic drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the patent expiration in key regions has introduced considerable volatility. Investors are now assessing the consequences of rival m